SPATA5L1

Across TCGA pan-cancer cohorts, SPATA5L1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SPATA5L1 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SPATA5L1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SPATA5L1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where SPATA5L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.820	0.331	<.001	68	view →
LUAD	DFS	Tertile	II,III,IV	0.225	0.747	<.001	64	view →
HNSC	OS	Quartile	IV	0.914	0.577	.016	11	view →
UCEC	DFS	Median	All	0.762	0.932	.006	6	view →
PDAC	DFS	Tertile	All	0.431	0.280	.010	6	view →
OV	DFS	Median	All	0.861	1.000	.030	4	view →
GBM	OS	Quartile	All	0.837	0.944	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SPATA5L1–CCRCC (DFS)

Open the CCRCC breakdown →